FORMULATION AND EVALUATION OF FLOATING DRUGS WITH IMPORTANCE OF FLOATING DRUG DELIVERY SYSTEM

Main Article Content

Satbir Singh
Dr Gaikwad Dushyant Dadabhau
Kehar Singh

Keywords

Formulation, evaluation, floating, drug delivery system

Abstract

The development of gastro retentive dosage forms was necessitated by the need to deliver medications at a specific region of the gastrointestinal tract, the so-called absorption window. Attempts to develop gastro retentive drug delivery systems can be broadly categorized into two groups: those that rely on the natural physiology of the gastrointestinal tract and those that are intended to circumvent it. Approaches such as size or floatation, which rely on delayed stomach evacuation, are dependent on the normal physiological fed state duration of 4 to 8 hours. Low density systems that cause buoyancy (Floating drug delivery system), high density which retains the dosage form in the stomach, raft forming systems, concomitant administration of drugs or excipients which slow the motility of the gastro intestinal tract, bioadhesion to gastric mucosa, and swelling to a large size which prevent passage of dosage form through the pyloric sphincter are the primary approaches studied for gastroretentive dosage forms. Floating Drug Delivery Systems (FDDS) have a lower bulk density than gastric fluids; consequently, they float in the stomach for an extended period of time without influencing the rate of gastric emptying. While the system is afloat on the gastric contents, the drug is slowly and nearly completely released from the system at the desired rate. After the drug's discharge, the residual system becomes susceptible to stomach emptying. This causes an increase in gastro retentive time, bioavailability, and improved control of plasma drug concentration fluctuations. Thus, the floating drug delivery system is a safe and effective drug delivery technology

Abstract 53 | pdf Downloads 27

References

1. Arnold DR, Granvil CP, Ward KW, Proksch JW. Quantitative determination of Besifloxacin Hydrochloride, a novel fluoroquinolone antimicrobial agent, in human tears by liquid chromatography-tandem mass spectrometry. J Chromatog B 2008; 867:105-110.
2. Balzli CL, Caballero AR, Tang A, Weeks AC, O´Callaghan RJ. Penetration and effectiveness of prophylactic fluoroquinolones in experimental methicillin- sensitive or methicillin-resistant Staphylococcus aureus anterior chamber infections. J Cataract Refract Surg. 2010; 36:2160–7.
3. Biju SS, Talegaonkar S, Mishra PR and Khar RK. Vesicular systems: An overview. Indian Journal of Pharmaceutical science. 2006; 68(2):141-153.
4. Chitra G, Vijay J, Upendra N. Formulation and optimization of thermosensitive in- situ gel of moxifloxacin Hydrochloride for ocular drug delivery. IJPPS. 2018; 10(3):123-130
5. Draize, John H., Woodard, Geoffrey and Calvery, Herbert O. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. Journal of Pharmacology and Experimental Therapeutics. 1944; 82: 377- 390.
6. Engels T, Forster T, Rybinsko WV. The influence of coemulsifier type on the stability of oil- in-water emulsions. Colloids Surf A Physicochem Eng Aspects. 1995; 99:141– 9.
7. Gunashekar GS, Krishna M. An Overview on Powder X-Ray Diffraction and HaBe A, Keipert S. Development and characterization of microemulsions for ocular application. Eur J Pharm Biopharm. 1997; 43:179–83.
8. Higuchi T: Rate of release of medicaments from ointment bases containing drugs in suspension. J. Pharm. Sci. 1961; 50: 847-875.
9. Hixson AW and Crowell JH. Dependence of Reaction Velocity upon surface and Agitation.
10. Hossain A, Alam S, Paul P. Development and Evaluation of Sustained Release Matrix Tablets of Indapamide using Methocel K15M CR Md. Journal of Applied Pharmaceutical Science. 2013;3(5):85-90
11. Huibers PD, Shah D. Evidence for synergism in non-ionic surfactant mixtures: enhancement of solubilization in water-inoil microemulsions. Langmuir. 1997; 13:5762–5.
12. ICH Harmonised Tripartite Guideline. Validation of Analytical Procedures: Text and Methodology Q2(R1). Available at: < http://www.ich.org/home.html >. Accessed on: 11 Nov 2016.
13. Its Current Applications. Research & Reviews: Journal of Physics. 2015; 4 (3):6- 10. Kawakami K, Yoshikawa T, Hayashi T, Nishihara Y, Masuda K. Microemulsion formulation for enhanced absorption of poorly soluble drugs. II. In vivo study. J Control Release. 2002; 81:75–82.
14. Korsmeyer RW, Gurny R, Doelker E, Buri P and Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. IJP. 1983; 15: 25-35
15. Kumar S, Kumar M, Majumdar DK, Sharma PK, Singh CL, Singh A. Development and Validation of Different Ultraviolet-Spectrophotometric Methods for the Estimation of Besifloxacin Hydrochloride in Different Simulated Body Fluids.
16. Márcia CN Costa, Amanda T Barden, Juliana MM Andrade, Tércio P Oppe, Elfrides ES Schapoval. Quantitative evaluation of Besifloxacin Hydrochloride ophthalmic suspension by HPLC, application to bioassay method and cytotoxicity studies.
17. Mohamed Firthouse PU, Mohamed Halith S, Wahab SU, Sirajudeen M,, Mohideen SK. Formulation and Evaluation of Miconazole Niosomes. International Journal of Pharm Tech Research. 2011; 3(2): 1019-1022.
18. Ninham BW, Chen SJ, Evans DF. Role of oils and other factors in microemulsion design. J Phys Chem. 1984; 88:5855–7.
19. OECD Guideline for testing of chemicals No. 405. Acute eye irritation/corrosion. Paris, France: OECD; 2012.